<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832153</url>
  </required_header>
  <id_info>
    <org_study_id>20181028</org_study_id>
    <nct_id>NCT03832153</nct_id>
  </id_info>
  <brief_title>Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes</brief_title>
  <acronym>PGCA-ACS</acronym>
  <official_title>Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HELLENIC CENTER FOR MARINE RESEARCH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Research and Technology Hellas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction with ST elevation (STEMI) is one of the leading causes of
      mortality. Although the presence of thrombus in STEMI patients has been linked to adverse
      outcomes, routine thrombus aspiration has not been proven effective. A potential explanation
      could be that patients with STEMI should be risk-stratified. Thus, a more personalized
      approach in treating these patients is stressfully required. This proposal aims to establish
      the required interdisciplinary infrastructure for developing a risk-stratification model by
      implementing clinical, laboratory and angiographic data with molecular knowledge obtained by
      using innovative technologies, such as data from nano/micro-Computed tomography and
      circulating microRNAs. Two hundred consecutive patients with STEMI undergoing thrombus
      aspiration will be enrolled in the study and will be followed-up for one year for Major
      Adverse Cardiac and Cerebrovascular events (MACCE). The proposed approach will shed light on
      the pathophysiological mechanisms and broaden the investigator's understanding of the complex
      cellular and molecular interactions in the STEMI setting that, along with clinical
      parameters, affect patient outcomes. Furthermore, it will enable the identification of
      certain circulating micro-RNAs as cardiovascular disease biomarkers and it will help
      clinicians to better stratify the cardiovascular and cerebrovascular risk of patients with
      STEMI. As part of the work, important characteristics of aspirated thrombi will be assessed
      for the first time (such as volume, density and shape) and will be linked to patient
      outcomes. All this information will be incorporated into one in-vitro model, which will be
      developed using bioprinting and microfluidics methodologies. The in-vitro model will
      facilitate: (i) the in-depth exploration of the pathophysiological mechanisms in patients
      with STEMI; and (ii) the therapeutic optimization of innovative nanocarriers/nanomedicines
      with thrombolytic efficacy. Clearly, the study improves personalized cardiovascular medicine
      approaches, by considering individual patient clinical assessment in a way that empowers the
      precision in diagnosis and therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fold changes of differentially-expressed microRNA from peripheral blood from patients suffering from STEMI (measured in log2 scale)</measure>
    <time_frame>12 months</time_frame>
    <description>The expression profiles of the total number of microRNAs that exist in the peripheral blood of patients suffering from STEMI will be analyzed using Next Generation Sequencing (NGS). Blood samples collected from the patients will be used to extract microRNAs through the application of suitable microRNA isolation kit (miRNeasy Serum/Plasma kit). Following, the miRNA library construction will be prepared using commercially available reagents (QIAseq miRNA Library kit). The quantification of miRNAs will be done by the Qubit dsDNA HS assay kit in the Qubit fluorometer before the cDNA library generation.Statistical analyses of differentially expressed miRNAs will be carried out using EdgeR by the generalized linear model. Fold changes of differentially-expressed microRNA will be measured in log2 scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of aspirated thrombus burden</measure>
    <time_frame>12 months</time_frame>
    <description>The volume of aspirated thrombi will be quantified (in mm3) using micro-CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression and post-procedural Thrombolysis in Myocardial Infarction (TIMI) flow</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale as described above) will be correlated to post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression (measured in log2 scale) with distal embolization</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale, as described above) will be correlated to distal embolization (dichotomous variable-yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNAs expression and volume of aspirated thrombus.</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNA (measured in log2 scale) will be correlated to the volume of aspirated thrombi (measured in mm3), as it will be quantified using micro-CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression and Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale) will be correlated to MACCE. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Thrombi</condition>
  <condition>MicroRNA</condition>
  <arm_group>
    <arm_group_label>patients with low thrombus burden</arm_group_label>
    <description>patients with the lower volume of aspirated thrombi, as measured using micro-CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with high thrombus burden</arm_group_label>
    <description>patients with the higher volume of aspirated thrombi, as measured using micro-CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thrombus aspiration</intervention_name>
    <description>Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.</description>
    <arm_group_label>patients with high thrombus burden</arm_group_label>
    <arm_group_label>patients with low thrombus burden</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Intracoronary blood samples will be collected (during thrombus aspiration) along with
      peripheral blood samples and will be analyzed for the presence of specific micro-RNAs.

      The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using
      the Micro/Nano-CT.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        210 consecutive patients presenting with STEMI and undergoing thrombus aspiration will be
        enrolled in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptoms of myocardial ischemia lasting for more than 30 minutes

          -  Definite ECG changes indicating STEMI

          -  Patients undergoing primary PCI within 12 hours from symptom onset

          -  Possibility to perform thrombus aspiration

          -  Written informed consent

        Exclusion Criteria:

          -  Treatment with fibrinolytic therapy for qualifying index STEMI event

          -  Patients with known intolerance to aspirin, ticagrelor or heparin

          -  Patients with active internal bleeding

          -  Patients with a recent history of intracranial hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Sianos</last_name>
    <role>Study Chair</role>
    <affiliation>Associate Professor of Cardiology, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Vizirianakis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitrios Fatouros</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor in Pharmaceutical Technology , Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eleftherios Angelis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor in Statistics, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Arvanitidis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Research, Hellenic Center for Marine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Michaelson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Pathology, Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Zacharopoulos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post-Doctoral Fellow, Hellenic Center for Marine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Ouzounis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Research, Centre for Research and Technology Hellas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Efstratios Karagiannidis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phd Candidate, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgios U Sianos</last_name>
    <phone>2310994837</phone>
    <phone_ext>0030</phone_ext>
    <email>gsianos@auth.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Efstratios U Karagiannidis</last_name>
    <phone>00306938943309</phone>
    <phone_ext>0030</phone_ext>
    <email>stratoskarag@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Sianos</last_name>
      <phone>2310994837</phone>
      <phone_ext>2310994837</phone_ext>
      <email>gsianos@auth.gr</email>
    </contact>
    <contact_backup>
      <last_name>Efstratios Karagiannidis</last_name>
      <phone>2310994837</phone>
      <phone_ext>2310994837</phone_ext>
      <email>stratoskarag@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Georgios Sianos</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioannis Vizirianakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitrios Fatouros</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleftherios Angelis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Arvanitidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Athanasios Zacharopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efstratios Karagiannidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Michaelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Ouzounis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. Epub 2007 Jul 30.</citation>
    <PMID>17692740</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.</citation>
    <PMID>28886621</PMID>
  </reference>
  <reference>
    <citation>Grover SP, Saha P, Jenkins J, Mukkavilli A, Lyons OT, Patel AS, Sunassee K, Modarai B, Smith A. Quantification of experimental venous thrombus resolution by longitudinal nanogold-enhanced micro-computed tomography. Thromb Res. 2015 Dec;136(6):1285-90. doi: 10.1016/j.thromres.2015.10.006. Epub 2015 Oct 9.</citation>
    <PMID>26489729</PMID>
  </reference>
  <reference>
    <citation>Vorpahl M, Foerst JR, Kelm M, Kaplan AV, Virmani R, Ball T. The complementary role of microCT and histopathology in characterizing the natural history of stented arteries. Expert Rev Cardiovasc Ther. 2011 Jul;9(7):939-48. doi: 10.1586/erc.11.81. Review.</citation>
    <PMID>21809975</PMID>
  </reference>
  <reference>
    <citation>Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008 Oct;18(10):997-1006. doi: 10.1038/cr.2008.282.</citation>
    <PMID>18766170</PMID>
  </reference>
  <reference>
    <citation>Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016 Sep;111(4):322-37. doi: 10.1093/cvr/cvw174. Epub 2016 Jun 29. Review.</citation>
    <PMID>27357636</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Karagiannidis Efstratios</investigator_full_name>
    <investigator_title>Medical Doctor (resident physician, Cardiology Department, AHEPA University hospital), PhD candidate, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bioprinting</keyword>
  <keyword>thrombus aspiration</keyword>
  <keyword>micro-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

